SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
AEON reported Third Quarter 2026 results. The price and volatility reaction is pending.
AEONearnings

Earnings reactions

AEON Biopharma, Inc. (AEON) Q3 FY2026 earnings

November 17, 2026 · SharpeIQ Research Desk

Reported results

  • Reported GAAP net income of $2.465 million for the three months ended September 30, 2026.
  • Reported GAAP research and development expenses of $1.515 million for the three months ended September 30, 2026.
  • Reported GAAP selling, general and administrative expenses of $2.990 million for the three months ended September 30, 2026.
  • Reported cash and cash equivalents of $11.417 million as of September 30, 2026.
  • Received approximately $6.2 million in gross proceeds from exercises of two-year milestone warrants.

Guidance

  • The Company expects its cash and cash equivalents as of September 30, 2026, together with warrant proceeds, to fund operations into the second quarter of 2027.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →